Previous
Next
PRIME IV
$400.00 15 minutes
ONOGEN’s signature universal blend of bioactive micronutrients, minerals and antioxidants specifically formulated to upgrade your biology by filling in nutritional and biomolecular gaps resulting from chronic stress.*
METABOLIC METHYL +
SEROTONINE / GABA +
IMMUNE C +
GLUTATHIONE GSH
Description
ONOGEN’s signature universal blend of bioactive micronutrients, minerals and antioxidants specifically formulated to upgrade your biology by filling in nutritional and biomolecular gaps resulting from chronic stress.*
What is it?
PRIME IV Formula is designed to provide YOU with our signature physician selection of specific biomolecular active ingredients – micronutrients, minerals and antioxidants. PRIME IV is the key therapy of our PRIME protocol, specifically designed to meet your unique biomolecular cellular needs based on our novel biohacking medical assessment delivered and analyzed by ONOGEN’s advanced algorithm-biotech-engine.
Your personalized PRIME protocol, may consist of one or multiple sessions depending on your personal biomolecular needs. Other oral supplements or testing may be added to your personalized plan to identify further possible deficiencies.
Our PRIME IV is formulated to be administered directly into your bloodstream by one of our Certified Biohacking doctors or RNs.
By bypassing the gut – going straight to your bloodstream – this protocol enhances the cellular delivery and uptake of specific biomolecular factors, micronutrients, antioxidants, and minerals, such as vitamin C, magnesium, methyl factors, active B’s, and glutathione, to support your nutritional status and cellular function, upgrading your biology to support you on your biohacking quest to become the healthiest, happiest and absolute best version of yourself.
** CURRENTLY IV THERAPY SERVICES ONLY AVAILABLE IN MIAMI-FT-LAUDERDALE-DAVIE-BOYTON BEACH-VEGAS & CARACAS.
NY & SAO PAULO COMING SOON!
How does it work?
STEP 1 | MEDICAL ASSESSMENT: Fill out Biohacking Medical Assessment to create your ONOGEN medical profiling.
STEP 2 | ADVANCED TESTING: Appropriate recommendations generated by our personalized biomolecular engine will be sent to you via email. A member of our biohacking concierge service may contact you to discuss any questions or concerns you may have.
STEP 3 | PERSONALIZED BIOHACKING PLAN: Choose your path and get your plan started. A member of our biohacking concierge service may contact you to schedule your appointment for IV Therapy visit, if you choose that path.
** CURRENTLY IV THERAPY SERVICES ONLY AVAILABLE IN MIAMI-FT-LAUDERDALE-DAVIE-BOYTON BEACH-VEGAS & CARACAS.
NY & SAO PAULO COMING SOON!
What are the benefits?
Most of our patient's report increased energy, vitality, exercise recovery, and brain power when regularly getting IV therapy. They have also noticed fewer colds.*
Our protocols have resulted in a 35% telomere increase in patients who have followed our protocols for at least a year.*
Active micronutrients- High dose Vitamin C
- Glutathione
- Magnesium and other key minerals
Active micronutrientsReferences
- Fenech M. Nutriomes and nutrient arrays - the key to personalized nutrition for DNA damage prevention and cancer growth control. Genome Integr 2010;1:11.
- Moores CJ, Fenech M, O'Callaghan NJ. Telomere dynamics: the influence of folate and DNA methylation. Ann NY Acad Sci 2011;1229:76-88.
- Paul L, Cattaneo M, D’Angelo A et al. Telomere Length in Peripheral Blood Mononuclear Cells is Associated with Folate Status in Men. J Nutr 2009;139:1273- 1278.
- Bull CF, O’Callaghan NJ, Mayrhofer G, Fenech MF. Telomere Length in Lymphocytes of Older South Australian Men May Be Inversely Associated with Plasma Homocysteine. Rejuvenation Res 2009;12:341-349.
- Serra V, von Zglinicki T, Lorenz M, Saretzki G. Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. J Biol Chem 2003;278:6824-6830.
- Martin H, Uring-Lambert B, Adrian M et al. Effects of long-term dietary intake of magnesium on oxidative stress, apoptosis and ageing in rat liver. Magnes Res 2008;21:124-130.
- Kurz D, Decary S, Hong Y et al. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004;117:2417-2426.
- Watfa G, Dragonas C, Brosche T et al. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging 2011;15:277-281.
- Furumoto K, Inoue E, Nagao N et al. Age-dependent telomere shortening is slowed down by enrichment of intracellular vitamin C via suppression of oxidative stress. Life Sci 1998;63:935-948.
- Yokoo S, Furumoto K, Hiyama E, Miwa N. Slow-down of age-dependent telomere shortening is executed in human skin keratinocytes by hormesis-like-effects of trace hydrogen peroxide or by anti-oxidative effects of pro-vitamin C in common concurrently with reduction of intracellular oxidative stress. J Cell Biochem 2004;93:588-597.
- Dröge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc. 2000 Nov;59(4):595-600.
- Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010 Feb 1;79(3):413-20.
- De Toro-martin J, Arsenault b, Despres JP, Vohl, MC. Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome Nutrients. 2017 Aug; 9(8): 913.Published online 2017 Aug 22.
- Tremblay J, Hamet P. Role of genomics on the path to personalized medicine. Metabolism. 2013 Jan;62 Suppl 1:S2-5.
- Katz D. Ather A, Yanchou Niike V, et al. Intravenous Micronutrient Therapy (Myers' Cocktail) for Fibromyalgia: A Placebo-Controlled Pilot Study J Altrn Comp Med. 2009 Mar; 15(3): 247–257.
- Gaby AR. Intravenous nutrient therapy: The “Myers' cocktail” Altern Med Rev. 2002;7:389–403.Yale-Griffin Prevention Research Center. Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia Syndrome: A Pilot Study. 2003. NIH, Grant #AT 00942–01A1.